HK1209758A1 - Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies - Google Patents
Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies Download PDFInfo
- Publication number
- HK1209758A1 HK1209758A1 HK15110286.5A HK15110286A HK1209758A1 HK 1209758 A1 HK1209758 A1 HK 1209758A1 HK 15110286 A HK15110286 A HK 15110286A HK 1209758 A1 HK1209758 A1 HK 1209758A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- type
- methods
- ifnar
- antibodies
- ifn
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N7/00—Computing arrangements based on specific mathematical models
- G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Data Mining & Analysis (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Primary Health Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Databases & Information Systems (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Probability & Statistics with Applications (AREA)
- Mathematical Optimization (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659138P | 2012-06-13 | 2012-06-13 | |
| US201261659138P | 2012-06-13 | ||
| PCT/US2013/045327 WO2013188494A1 (en) | 2012-06-13 | 2013-06-12 | Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1209758A1 true HK1209758A1 (en) | 2016-04-08 |
Family
ID=49758685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15110286.5A HK1209758A1 (en) | 2012-06-13 | 2013-06-12 | Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9493570B2 (enExample) |
| EP (1) | EP2861621A4 (enExample) |
| JP (5) | JP2015526391A (enExample) |
| KR (3) | KR102185237B1 (enExample) |
| CN (3) | CN104603152A (enExample) |
| AU (3) | AU2013274389A1 (enExample) |
| CA (1) | CA2876636C (enExample) |
| HK (1) | HK1209758A1 (enExample) |
| WO (1) | WO2013188494A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643237T3 (es) * | 2004-06-21 | 2017-11-21 | E. R. Squibb & Sons, L.L.C. | Anticuerpos del receptor 1 de interferón alfa y sus usos |
| KR100680048B1 (ko) * | 2006-01-23 | 2007-02-08 | 쌍용자동차 주식회사 | 자동차 도장용 크레인의 구조 |
| CN108699608A (zh) * | 2015-10-09 | 2018-10-23 | 基因前沿公司 | 用于预测和诊断人巨细胞病毒(hCMV)先天性传播的方法和试剂盒 |
| MA45554A (fr) | 2016-07-01 | 2019-05-08 | Resolve Therapeutics Llc | Fusions de binucléase optimisées. |
| CN106243226B (zh) * | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| US20200031943A1 (en) | 2017-03-21 | 2020-01-30 | Austrianni Gmbh | Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases |
| CN111315767B (zh) | 2017-08-22 | 2025-03-18 | 萨纳生物有限责任公司 | 可溶性干扰素受体及其用途 |
| US11139051B2 (en) | 2018-10-02 | 2021-10-05 | Origent Data Sciences, Inc. | Systems and methods for designing clinical trials |
| CA3117102A1 (en) | 2018-10-26 | 2020-04-30 | Janssen Biotech, Inc. | Type i interferon signatures and methods of use |
| JP7386877B2 (ja) | 2019-01-31 | 2023-11-27 | イミューンセント バイオテクノロジー,インコーポレイテッド | 新規の抗ifnar1抗体 |
| CN111892653A (zh) * | 2019-07-03 | 2020-11-06 | 长春恒晓生物科技有限责任公司 | 制备粘病毒抗性蛋白1抗体及建立检测mx1方法 |
| TW202317617A (zh) * | 2021-04-23 | 2023-05-01 | 瑞典商阿斯特捷利康公司 | 皮膚紅斑狼瘡之治療 |
| AU2022260544A1 (en) | 2021-04-23 | 2023-11-30 | Astrazeneca Ab | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
| SMT202300382T1 (it) * | 2021-04-23 | 2024-01-10 | Astrazeneca Ab | Regime di dosaggio anti-ifnar1 per iniezione sottocutanea |
| AU2022317215A1 (en) * | 2021-07-27 | 2024-02-29 | Astrazeneca Ab | Treatment of lupus |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202402824D0 (en) * | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044406A1 (en) * | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| US20040037809A1 (en) * | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
| ES2643237T3 (es) * | 2004-06-21 | 2017-11-21 | E. R. Squibb & Sons, L.L.C. | Anticuerpos del receptor 1 de interferón alfa y sus usos |
| WO2006128210A1 (en) * | 2005-06-03 | 2006-12-07 | John Arthur Notaras | A tiller |
| AU2006259583A1 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| CA2651866C (en) * | 2006-05-11 | 2014-10-28 | Universiteit Gent | Sialoadhesin-related compositions and methods |
| CN101594882A (zh) * | 2006-12-06 | 2009-12-02 | 米迪缪尼有限公司 | 干扰素α诱导的药代动力学标记物 |
| WO2008070135A2 (en) * | 2006-12-06 | 2008-06-12 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
| AU2008324800B2 (en) * | 2007-11-05 | 2014-03-27 | Astrazeneca Ab | Methods of treating scleroderma |
| MX2010008578A (es) * | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
| US20110287022A1 (en) * | 2008-06-20 | 2011-11-24 | Medlmmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| KR20110044905A (ko) * | 2008-08-15 | 2011-05-02 | 메리맥 파마슈티컬즈, 인크. | 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템 |
| SMT201700063T1 (it) | 2009-09-03 | 2017-03-08 | Medimmune Llc | Diagnosi di interferoni di tipo 1 |
-
2013
- 2013-06-12 CN CN201380043349.7A patent/CN104603152A/zh active Pending
- 2013-06-12 KR KR1020147037151A patent/KR102185237B1/ko active Active
- 2013-06-12 JP JP2015517382A patent/JP2015526391A/ja active Pending
- 2013-06-12 EP EP13803921.9A patent/EP2861621A4/en not_active Withdrawn
- 2013-06-12 CN CN201810164604.8A patent/CN108310375A/zh active Pending
- 2013-06-12 AU AU2013274389A patent/AU2013274389A1/en not_active Abandoned
- 2013-06-12 US US14/407,156 patent/US9493570B2/en active Active
- 2013-06-12 HK HK15110286.5A patent/HK1209758A1/xx unknown
- 2013-06-12 CA CA2876636A patent/CA2876636C/en active Active
- 2013-06-12 WO PCT/US2013/045327 patent/WO2013188494A1/en not_active Ceased
- 2013-06-12 CN CN202010333445.7A patent/CN111494624A/zh active Pending
- 2013-06-12 KR KR1020217034200A patent/KR20210130270A/ko not_active Ceased
- 2013-06-12 KR KR1020207033413A patent/KR102320059B1/ko active Active
-
2017
- 2017-12-01 JP JP2017231307A patent/JP2018065845A/ja active Pending
-
2018
- 2018-07-23 AU AU2018206851A patent/AU2018206851C1/en active Active
-
2019
- 2019-02-27 JP JP2019033979A patent/JP6814238B2/ja active Active
-
2020
- 2020-07-10 AU AU2020204613A patent/AU2020204613B2/en active Active
- 2020-10-16 JP JP2020174325A patent/JP2021042208A/ja not_active Ceased
-
2021
- 2021-07-07 JP JP2021112707A patent/JP7123225B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210130270A (ko) | 2021-10-29 |
| KR102185237B9 (ko) | 2021-08-06 |
| CA2876636A1 (en) | 2013-12-19 |
| CN111494624A (zh) | 2020-08-07 |
| JP7123225B2 (ja) | 2022-08-22 |
| KR102320059B1 (ko) | 2021-11-01 |
| JP2015526391A (ja) | 2015-09-10 |
| AU2020204613A1 (en) | 2020-07-30 |
| AU2018206851A1 (en) | 2018-08-09 |
| US20150158949A1 (en) | 2015-06-11 |
| EP2861621A1 (en) | 2015-04-22 |
| AU2020204613B2 (en) | 2021-10-07 |
| AU2018206851C1 (en) | 2021-11-25 |
| JP6814238B2 (ja) | 2021-01-13 |
| CN104603152A (zh) | 2015-05-06 |
| KR20200133395A (ko) | 2020-11-27 |
| AU2013274389A1 (en) | 2015-01-22 |
| JP2018065845A (ja) | 2018-04-26 |
| US9493570B2 (en) | 2016-11-15 |
| CA2876636C (en) | 2022-09-13 |
| JP2019112429A (ja) | 2019-07-11 |
| KR102185237B1 (ko) | 2020-12-02 |
| JP2021167336A (ja) | 2021-10-21 |
| KR20150035825A (ko) | 2015-04-07 |
| JP2021042208A (ja) | 2021-03-18 |
| WO2013188494A1 (en) | 2013-12-19 |
| AU2018206851B2 (en) | 2020-07-30 |
| EP2861621A4 (en) | 2016-01-20 |
| CN108310375A (zh) | 2018-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
| BR112013018932A2 (pt) | polipeptídeo de interleucina-2 mutante, imunoconjugado, polinucleotídeo isolado, vetor de expressão, célula hospedeira, método de produção de um polipeptídeo de il-2 mutante ou um imunoconjugado do mesmo, composição farmacêutica, uso, método de tratamento de uma doença em um indivíduo e método de estimulação do sistema imunológico de um indivíduo | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| JP2015524397A5 (enExample) | ||
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| BR112015005048A8 (pt) | métodos para tratar dermatite atópica por administração de antagonista il-4r | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| EA201691399A1 (ru) | Способы и готовые лекарственные формы для лечения болезни альцгеймера | |
| MX392618B (es) | Un anticuerpo monoclonal de anti-beta7 para usarse en el tratamiento de un trastorno inflamatorio gastrointestinal. | |
| MX2013003929A (es) | Biomarcadores de citoquina como marcadores predictivos de respuesta clinica para acetato de glatiramer. | |
| HK1220474A1 (zh) | 干扰素α和ω抗体拮抗剂 | |
| WO2016110806A3 (en) | Dosage regimen for madcam antagonists | |
| PH12013500108A1 (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| BR112014025768A2 (pt) | métodos de tratamento de espondilite anquilosante usando antagonistas de il-17 | |
| MX2020006660A (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato. | |
| BR112014011758A2 (pt) | composição farmacêutica, proteína de fusão, polinucleotídeo, vetor, célula isolada, métodos para produzir uma proteína de fusão, para tratar ou previnir uma doença ou condição, para diagnosticar a suscetibilidade de um indivíduo a desenvolver uma doença ou condição, para determinar uma adequabilidade do indivíduo para ingressar em um experimento de classificação dedroga, e para identificar um agente, uso de uma combinação, e, combinação. | |
| BR112014027905A2 (pt) | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. | |
| WO2013071012A3 (en) | Personalized strategic cancer treatment | |
| Chua et al. | Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer | |
| EA201401353A1 (ru) | Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк) | |
| WO2016014799A9 (en) | Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy | |
| EP2861621A4 (en) | SOLID DOSAGE SCHEDULES FOR ANTI-TYPE-1 INTERFERON RECEPTOR (IFNAR) ANTIBODY | |
| Johnson‐Ansah et al. | Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia | |
| WO2012109233A3 (en) | Methods for predicting recurrence risk in breast cancer patients |